• First biologic other than anti-TNFs launched in India
 

• Vedolizumab, a gut-specific anti-integrin is found to have a lower risk of activation of latent tuberculosis and other infections which is important an Indian perspective

​

• An additional biologic in the armamentarium of IBD management as anti-TNF failures are increasingly being recognized